Breast cancer trial starts with good news
Published: April 15, 2008 at 12:37 PM
In the groundbreaking trial, University of Michigan Medical School researchers are combining chemotherapy with a drug that blocks the Notch signaling pathway that helps regulate fetal development and is active in most organ systems throughout a person's life.
The aim is to use so-called Notch inhibitors to attack cancer stem cells. But a big concern is that the Notch inhibitors, while helping destroy cancer stem cells, might also kill healthy stem cells critical to a patient's survival.
However, a recent study conducted by UM Assistant Professor Ivan Maillard and colleagues might allay those fears. The researchers showed that blood-forming stem cells in mice survive when their Notch signaling pathway is experimentally blocked.
"Our data indicate that normal blood-forming stem cells should not be damaged by the Notch inhibitor drug being used in these patients," said Maillard.
The research that included scientists from the University of Pennsylvania, the Swiss Institute for Experimental Cancer Research and the Harvard Medical School appears in the journal Cell Stem Cell.
© 2008 United Press International. All Rights Reserved.
This material may not be reproduced, redistributed, or manipulated in any form.
This material may not be reproduced, redistributed, or manipulated in any form.
» Next in Science:
Potential diabetes drug target identified
A crane lowers space shuttle Discovery toward the external tank and solid rocket boosters already stacked on the mobile launcher platform in high bay 3 of the Vehicle Assembly Building at Kennedy Space Center, Flordia. The stacking and mating took place in preparation for the launch on the STS-124 mission to the International Space Station, targeted to launch on May 31, 2008. (UPI Photo/Jim Grossmann/NASA)
Space Shuttle Discovery set to launch on May 31
Full Photo
| Slideshow
Latest Headlines
Most Popular